APPLIED DNA SCIENCES INC (APDN)

Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement

Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application

Applied DNA Launches Mpox Clade I and Clade II Testing Service

Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan

Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?

Applied DNA Sciences, Inc. (NASDAQ:APDN) stock traded higher on Friday on a strong session volume of 114.23 million, compared to the average volume of 6.78 million, according to data from Benzinga Pro. The PCR-based DNA technologies submitted a validation package to the New York State Department of Health (NYSDOH) to expand the permitted use of its Linea Mpox Virus 1.0 Assay to include both mpox clade I and clade II. The company’s validation studies concluded that the Assay’s primers and probe h

Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

APDN Stock Earnings: Applied DNA Sciences Reported Results for Q3 2024

Applied DNA Sciences just reported results for the third quarter of 2024.

APDN Stock Earnings: Applied DNA Sciences Reported Results for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Applied DNA Sciences (NASDAQ:APDN) just reported results for the third quarter ...

Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit

Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability

U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth diving into this morning as we break down all of the biggest news moving shares on Tuesday!

Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics